BCDA Company Profile and Key Details

BioCardia, Inc. generated EPS of -$1.73 over the past year. Five-year average earnings growth is 40.58%. Wall Street analysts project EPS growth of 34.77% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.17. Next year's EPS is expected at -$7.62. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $25.00. The high target offers 2193.58% upside. The low target suggests 2193.58% downside. The mean target is $25.00. This offers 2193.58% upside. BioCardia, Inc. earnings surprise history is a mixed track record. The quarter that ended March 24, 2026, missed forecasts by -70.0%. The prior quarter beat by -4.0%. Over the last six quarters, Apple has recorded several small beats. These include -48.74% in November 13, 2024.

Short-term trend indicators are bullishly aligned (SMA20 4.09%, SMA50 -1.68%, SMA200 -25.93%). The stock’s 14-day RSI is 52.54 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -61.25% below its high and over 24.0% above its low. Average 10-day trading volume of 736.57 thousand shares is significantly above the 3-month average of 160.87 thousand, indicating heightened recent market interest.

BioCardia, Inc. has 10.61 million shares outstanding. The public float is 7.22 million shares, elevated short interest at 2.18% of float. This equals 192.26 thousand shares. The short ratio is 3.64 days. Institutional investors hold 6.48% of the float. Insiders own 18.98%. FROST PHILLIP MD ET AL holds 1.90 million shares, Allen Jim L. has 668.20 thousand shares and Blank Andrew Scott has 602.52 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

BioCardia, Inc. (NASDAQ:BCDA) closed at $1.09 USD, gaining $0.02 (1.87%) from the previous close of $1.07. The stock is currently mid-range between its 52-week high and low $1.00 and $2.49. With a market capitalization of about $6.32 million, BioCardia, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.55). Key stats such as the average daily volume over the past year has been around 150.14 thousand shares, in line with its 52-week average. Headquartered in Sunnyvale, CA, BioCardia, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter A. Altman, the company employs approximately 17 people and listed since November 13, 1996. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

BioCardia, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.30. This means the shares are trading above this model’s fair value.

BioCardia, Inc. trades at a P/E ratio of -1.41, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 12.99 reflecting a rich premium to book value. The P/FCF stands at -0.84, also above market averages. Compared to sector medians, BioCardia, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that BioCardia, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.42%, with price expected at $1.02 by May 28, 2026, within a range of $1.00 to $1.04 3-Month Outlook: Projected rise of 38.53%, reaching $1.51 by August 12, 2026, with a range of $1.38 to $1.62. 1-Year Outlook: Projected loss of -69.72%, with price at $0.33 by May 14, 2027, within a range of $0.00 to $0.40.

BioCardia, Inc. (NASDAQ:BCDA) shares are flat 4.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioCardia, Inc. trading at a premium to the broader market with a P/E of -1.41. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.08, suggesting 1100.0% upside. Our AI forecast model points to short-term weakness (-6.42% over two weeks), a medium-term rise (38.53% over three months), and a longer-term loss (-69.72% over one year), with expected trading ranges indicating moderate volatility.